Home › Companies › ALX Oncology Holdings Inc. › 2024-2025
At ALX Oncology Holdings Inc.'s shareholder meeting held June 11, 2025, in the 2024-2025 proxy season, 86 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 429 separate fund positions. On the most widely held item on that ballot — ADVISORY VOTE TO APPROVE NAMED EXECUTIVE OFFICER COMPENSATION. — ALX Oncology Holdings Inc.'s filing reports the proposal as approved, with 72% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ALX Oncology Holdings Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2025.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ALX Oncology Holdings Inc.’s Form 8-K, filed June 12, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 11, 2025: 4 items on ALX Oncology Holdings Inc.’s Form 8-K, filed June 12, 2025: 2 elected · 2 approved.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore ALX Oncology Holdings Inc. in the interactive database Compare manager voting policies
These tallies are ALX Oncology Holdings Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Scott Garland | 23,602,975 | -- | -- | 8,662,965 | 11,796,795 | 73% | Elected | — |
| Elect Director: Barbara Klencke, M.D. | 30,835,565 | -- | -- | 1,430,375 | 11,796,795 | 96% | Elected | — |
| 2. Advisory Vote on the Compensation of the Company's Named Executive Officers | 22,147,884 | 8,736,683 | 1,381,373 | -- | 11,796,795 | 72% | Approved | — |
| 3. Ratification of the Appointment of Independent Registered Public Accounting Firm | 41,776,769 | 59,969 | 2,225,997 | -- | -- | 99.8% | Approved | — |
Source: ALX Oncology Holdings Inc., Form 8-K, filed with the SEC on June 12, 2025 — read the filing on EDGAR.
Each item below shows how the 86 asset managers that disclosed a ALX Oncology Holdings Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Barbara Klencke, M.D.
ALX Oncology Holdings Inc.’s own tally for this item (“Elect Director: Barbara Klencke, M.D.”): 30,835,565 for, 1,430,375 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Two Class II Directors Each director nominee was duly elected to serve until the 2028 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 29 asset managers below reported 2,367,890 for, 1,291 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 749,172 | 0 | 0 | 0 | For |
| Vanguard | 645,315 | 0 | 0 | 0 | For |
| SEI | 288,950 | 0 | 0 | 0 | For |
| Charles Schwab | 212,477 | 0 | 0 | 0 | For |
| Equitable | 114,856 | 0 | 0 | 0 | For |
| Aberdeen | 66,211 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 65,861 | 0 | 0 | 0 | For |
| Goldman Sachs | 38,343 | 0 | 0 | 0 | For |
| Northern Trust | 34,935 | 0 | 0 | 0 | For |
| Lincoln Financial | 26,200 | 0 | 0 | 0 | For |
| Fidelity | 20,535 | 0 | 0 | 0 | For |
| Global X | 19,397 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 17,599 | 0 | 0 | 0 | For |
| Pacific Life | 12,217 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 12,000 | 0 | 0 | 0 | For |
| Nationwide | 8,081 | 0 | 0 | 0 | For |
| ProShares | 6,881 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 6,478 | 0 | 0 | 0 | For |
| DWS | 5,859 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 4,859 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,490 | 0 | 0 | 0 | For |
| Calvert | 2,790 | 0 | 0 | 0 | For |
| State Street | 1,397 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 0 | 1,291 | Withhold |
| TIAA | 1,043 | 0 | 0 | 0 | For |
Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
73% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Scott Garland
ALX Oncology Holdings Inc.’s own tally for this item (“Elect Director: Scott Garland”): 23,602,975 for, 8,662,965 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Two Class II Directors Each director nominee was duly elected to serve until the 2028 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.”
Support: 73% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 29 asset managers below reported 684,811 for, 862,859 withheld, 821,511 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 0 | 0 | 749,172 | 0 | Abstain |
| Vanguard | 645,315 | 0 | 0 | 0 | For |
| SEI | 0 | 0 | 0 | 288,950 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 212,477 | Withhold |
| Equitable | 0 | 0 | 0 | 114,856 | Withhold |
| Aberdeen | 0 | 0 | 0 | 66,211 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 65,861 | 0 | Abstain |
| Goldman Sachs | 0 | 0 | 0 | 38,343 | Withhold |
| Northern Trust | 0 | 0 | 0 | 34,935 | Withhold |
| Lincoln Financial | 26,200 | 0 | 0 | 0 | For |
| Fidelity | 0 | 0 | 0 | 20,535 | Withhold |
| Global X | 0 | 0 | 0 | 19,397 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 17,599 | Withhold |
| Pacific Life | 0 | 0 | 0 | 12,217 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 12,000 | Withhold |
| Nationwide | 0 | 0 | 0 | 8,081 | Withhold |
| ProShares | 0 | 0 | 0 | 6,881 | Withhold |
| Bridge Builder Trust | 0 | 0 | 6,478 | 0 | Abstain |
| DWS | 0 | 0 | 0 | 5,859 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 4,859 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,490 | 0 | 0 | 0 | For |
| Calvert | 0 | 0 | 0 | 2,790 | Withhold |
| State Street | 1,397 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 0 | 1,291 | Withhold |
| TIAA | 1,043 | 0 | 0 | 0 | For |
Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
72% Approved · of votes cast
Description as filed by funds: ADVISORY VOTE TO APPROVE NAMED EXECUTIVE OFFICER COMPENSATION.
ALX Oncology Holdings Inc.’s own tally for this item (“2. Advisory Vote on the Compensation of the Company's Named Executive Officers”): 22,147,884 for, 8,736,683 against — passed, per its Form 8-K filed June 12, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the proxy statement for the Annual Meeting.”
Support: 72% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 0 | 749,172 | 0 | 0 | Against |
| Vanguard | 645,315 | 0 | 0 | 0 | For |
| SEI | 288,950 | 0 | 0 | 0 | For |
| Charles Schwab | 212,477 | 0 | 0 | 0 | For |
| Equitable | 0 | 114,856 | 0 | 0 | Against |
| Aberdeen | 0 | 66,211 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 0 | 65,861 | 0 | 0 | Against |
| Goldman Sachs | 0 | 38,343 | 0 | 0 | Against |
| Northern Trust | 34,935 | 0 | 0 | 0 | For |
| Lincoln Financial | 26,200 | 0 | 0 | 0 | For |
| Fidelity | 0 | 20,535 | 0 | 0 | Against |
| Global X | 19,397 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 17,599 | 0 | 0 | Against |
| Pacific Life | 0 | 12,217 | 0 | 0 | Against |
| Blackstone Alternative Investment Funds | 0 | 12,000 | 0 | 0 | Against |
| Nationwide | 2,442 | 5,639 | 0 | 0 | Mixed |
| ProShares | 0 | 6,881 | 0 | 0 | Against |
| Bridge Builder Trust | 0 | 6,478 | 0 | 0 | Against |
| DWS | 0 | 5,859 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 4,859 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 4,490 | 0 | 0 | Against |
| Calvert | 0 | 2,790 | 0 | 0 | Against |
| State Street | 1,397 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 1,291 | 0 | Abstain |
| TIAA | 0 | 1,043 | 0 | 0 | Against |
Fund voting reports, all 29 managers: 1,237,479 for, 1,130,411 against, 1,291 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Redmile Group, LLC | 3,513,911 | 0 | 0 | 0 | For |
| BlackRock | 23,949 | 449,425 | 0 | 0 | Mixed |
| State Street | 369,519 | 1,605 | 0 | 0 | For |
| SEI | 289,055 | 0 | 0 | 0 | For |
| Two Sigma | 0 | 260,795 | 0 | 0 | Against |
| Charles Schwab | 212,477 | 0 | 0 | 0 | For |
| Northern Trust | 195,423 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 0 | 115,468 | 0 | 0 | Against |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 0 | 113,545 | 0 | 0 | Against |
| MPM BioImpact LLC | 101,265 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 92,117 | 0 | 0 | 0 | For |
| Vanguard | 44,968 | 32,291 | 0 | 0 | Mixed |
| AllianceBernstein | 0 | 71,730 | 0 | 0 | Against |
| Invesco | 0 | 70,929 | 0 | 0 | Against |
| Aberdeen | 0 | 66,211 | 0 | 0 | Against |
| Nuveen | 0 | 61,838 | 0 | 0 | Against |
| AQR | 0 | 61,107 | 0 | 0 | Against |
| DE Shaw | 0 | 39,000 | 0 | 0 | Against |
| Goldman Sachs | 0 | 35,384 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 23,560 | 0 | 0 | Against |
| Lynx1 Capital Management LP | 16,982 | 0 | 0 | 0 | For |
| JPMorgan | 15,592 | 0 | 0 | 0 | For |
| MONETA GROUP INVESTMENT ADVISORS LLC | 0 | 15,196 | 0 | 0 | Against |
| NEW YORK STATE COMMON RETIREMENT FUND | 12,522 | 0 | 0 | 0 | For |
| Fidelity | 0 | 12,066 | 0 | 0 | Against |
Institutional-manager reports, all 67 managers: 4,925,880 for, 1,491,244 against. Showing the 25 largest; every one is in the interactive database (link above).
99.8% Approved · of votes cast
Description as filed by funds: Ratification of the appointment of KPMG LLP as the independent registered public accounting firm for our fiscal year ending December 31, 2025.
ALX Oncology Holdings Inc.’s own tally for this item (“3. Ratification of the Appointment of Independent Registered Public Accounting Firm”): 41,776,769 for, 59,969 against — passed, per its Form 8-K filed June 12, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3: Ratification of the Appointment of Independent Registered Public Accounting Firm”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 29 asset managers below reported 2,367,890 for, 1,291 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 749,172 | 0 | 0 | 0 | For |
| Vanguard | 645,315 | 0 | 0 | 0 | For |
| SEI | 288,950 | 0 | 0 | 0 | For |
| Charles Schwab | 212,477 | 0 | 0 | 0 | For |
| Equitable | 114,856 | 0 | 0 | 0 | For |
| Aberdeen | 66,211 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 65,861 | 0 | 0 | 0 | For |
| Goldman Sachs | 38,343 | 0 | 0 | 0 | For |
| Northern Trust | 34,935 | 0 | 0 | 0 | For |
| Lincoln Financial | 26,200 | 0 | 0 | 0 | For |
| Fidelity | 20,535 | 0 | 0 | 0 | For |
| Global X | 19,397 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 17,599 | 0 | 0 | 0 | For |
| Pacific Life | 12,217 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 12,000 | 0 | 0 | 0 | For |
| Nationwide | 8,081 | 0 | 0 | 0 | For |
| ProShares | 6,881 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 6,478 | 0 | 0 | 0 | For |
| DWS | 5,859 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 4,859 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 4,490 | 0 | 0 | 0 | For |
| Calvert | 2,790 | 0 | 0 | 0 | For |
| State Street | 1,397 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 0 | 1,291 | 0 | Abstain |
| TIAA | 1,043 | 0 | 0 | 0 | For |
Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 53,444,020 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 1.40% |
| 2 | Vanguard | 1.21% |
| 3 | SEI | 0.54% |
| 4 | Charles Schwab | 0.40% |
| 5 | Equitable | 0.21% |
| 6 | Aberdeen | 0.12% |
| 7 | QUANTITATIVE MASTER SERIES LLC | 0.12% |
| 8 | Goldman Sachs | 0.07% |
| 9 | Northern Trust | 0.07% |
| 10 | Lincoln Financial | 0.05% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Redmile Group, LLC | 6.57% |
| 2 | BlackRock | 0.89% |
| 3 | State Street | 0.69% |
| 4 | SEI | 0.54% |
| 5 | Two Sigma | 0.49% |
| 6 | Charles Schwab | 0.40% |
| 7 | Northern Trust | 0.37% |
| 8 | MELLON INVESTMENTS Corp | 0.22% |
| 9 | STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 0.21% |
| 10 | MPM BioImpact LLC | 0.19% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| RA Capital Management, L.P. | — | 13G |
| Chen Yu | — | 13G |
| Adelman Robert J | — | 13D |
| Redmile Group, LLC | — | 13G |
| HBM Healthcare Investments (Cayman) Ltd. | — | 13G |
| Michael A Carusi | — | 13D |
| BlackRock | — | 13F |
| Vanguard Group | — | 13F |
| Millennium Management | — | 13F |
| Geode Capital | — | 13F |
Percentages above are of 53,444,020 shares outstanding, as reported by ALX Oncology Holdings Inc. on its Form 10-Q dated May 1, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ALX Oncology Holdings Inc.’s 10-Q dated May 1, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
ALX Oncology Holdings Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
proxyvotesnow.com, “ALX Oncology Holdings (ALXO) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/alx-oncology-holdings-inc/2025 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.